TheEdgeResearch
Home / Stocks / FAMDF

Futura Medical plc (FAMDF)

OTC Healthcare Biotechnology
$0.00 ▲ +0.00%
Market Cap
$678,664
Sector
Healthcare
Industry
Biotechnology
Beta
0.00
52-Wk Range
0.0014-0.05
CEO
Alex Duggan
Country
GB
Currency
USD

Futura Medical plc operates in the Biotechnology industry of the Healthcare sector, headquartered in Guildford, SU, GB. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $678,664. On trailing twelve-month figures it carries a trailing P/E of -0.31, a net margin of -158.2%. Its beta of 0.00 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-0.31
Price / Sales
0.28
Price / Book
0.56
EV / EBITDA
3.86
Gross margin
110.6%
Operating margin
-9.9%
Net margin
-158.2%
Return on equity
—
Debt / equity
0.00
Current ratio
1.82
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
14
IPO date
2012-05-15
Headquarters
Guildford, SU, GB
About Futura Medical plc

Futura Medical plc operates as a pharmaceutical firm specializing in the creation and advancement of consumer healthcare products. The company primarily targets the sexual health and pain management sectors. Its leading innovation is MED3000, a topical gel specifically formulated to treat erectile dysfunction. Additionally, Futura Medical offers a variety of pain relief solutions, including TPR100, a topical diclofenac gel; CBD100, a cannabidiol-based topical application; and TIB200, an ibuprofen topical gel. Established in 2001, the company is headquartered in Guildford, United Kingdom.

Comparable companies

Futura Medical plc is most often compared with the following Healthcare names:

BVAXFBZYRCLABFENSCKNBIFMYNDFPCLOFSRNETHERVDQSF
More research on FAMDF
FAMDF technical analysis FAMDF TheEdge Score Compare against peers
Open full interactive analysis & DCF →